- Home
- BALY vs ARVN Comparison
BALY vs ARVN Comparison
Compare BALY & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BALY | ARVN |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | 11700 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 711.1M | 600.2M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BALY | ARVN |
|---|---|---|
| Price | $13.51 | $7.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 16 |
| Target Price | $9.67 | ★ $13.93 |
| AVG Volume (30 Days) | 76.1K | ★ 670.8K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.37 | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | ★ $2,436,189,000.00 | $262,600,000.00 |
| Revenue This Year | $19.09 | $12.76 |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | ★ N/A | $4.62 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.44 | $6.74 |
| 52 Week High | $19.60 | $14.22 |
Technical Indicators
Market Signals| Indicator | BALY | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 55.02 |
| Support Level | $13.38 | $6.74 |
| Resistance Level | $14.20 | $8.52 |
| Average True Range (ATR) | 0.57 | 0.37 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 52.04 | 88.37 |
Price Performance
Historical ComparisonAbout BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, entertainment, and technology company operating across casino, interactive, and lottery markets. It provides physical and interactive gaming experiences, including casino gaming, iGaming, sportsbook, online bingo, free-to-play games, and technology-driven lottery solutions. The company's segments include Casinos & Resorts, which generates maximum revenue and operates casino and resort properties, a horse racetrack, and a golf course; Bally's Intralot B2B, which provides lottery and technology services; Bally's Intralot B2C, which includes interactive gaming and lottery operations, including a UK casino; and North America Interactive, which includes sports betting and iGaming operations in the United States and Canada.
About ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.